Novartis AG (NVS) |
| 162.46 1.21 (0.75%) 09-02 16:00 |
| Open: | 160.8 |
| High: | 163.16 |
| Low: | 160.38 |
| Volume: | 4,342,915 |
| Market Cap: | 308,790(M) |
| PE Ratio: | 18.7 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 191.05 |
| Resistance 1: | 163.57 |
| Pivot price: | 156.29 |
| Support 1: | 154.62 |
| Support 2: | 149.09 |
| 52w High: | 170.46 |
| 52w Low: | 121.57 |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Financials
| EPS | 6.620 |
| Book Value | 21.860 |
| PEG Ratio | 3.63 |
| Gross Profit | 22.374 |
| Profit Margin (%) | 22.50 |
| Operating Margin (%) | 34.62 |
| Return on Assets (ttm) | 10.3 |
| Return on Equity (ttm) | 30.4 |
Company news
Wed, 02 Sep 2026
Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B - seekingalpha.com
Tue, 01 Sep 2026
US Stock Market Movements | Novartis AG (NVS.US) Rises Over 5% as Late-Stage Trials for Oral MS Drug Succeed - Moomoo
Tue, 01 Sep 2026
Novartis AG (NVS) Holds Entresto Edge As Earnings Strengthen - StocksToTrade
Tue, 01 Sep 2026
Novartis NVS Stock Holds Gains As Entresto Win, Q2 Growth Impress Traders - timothysykes.com
Tue, 01 Sep 2026
Novartis Rallies After Positive Late-Stage Multiple Sclerosis Trial Results - Quiver Quantitative
Tue, 01 Sep 2026
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
